Alerta

NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS

Resumen de: AU2023392764A1

There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 µm; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide.

USE OF NANO CARRIERS FOR DELIVERY OF ACTIVE AGENTS

Resumen de: AU2025203999A1

There are disclosed uses of compositions for the preparation of medications for the treatment of a subject or an object in need thereof, the compositions comprising nano-elements containing: a) at least one water-insoluble thermoplastic compound (WITC), capable of forming a core; and b) at least one active agent which can be disposed in said core or in shells surrounding the core. The nano-elements, having an average diameter in the sub micron range, are constituted of materials having a low vapor pressure and are dispersible in a polar carrier. Methods for preparing these nano-elements, and administering them, so as to treat conditions corresponding to the active agents contained therein, are also provided.

LIPID NANOPARTICLES COMPRISING ENCAPSULATED PROTEINS AND USES THEREOF

Resumen de: WO2025129183A1

Provided herein are lipid nanoparticles comprising an anionic lipid component, wherein the lipid nanoparticles comprise a hydrophilic protein that is encapsulated in the lumen of the lipid nanoparticles. Methods of making and using the lipid nanoparticles are also provided. Also included are methods of editing the genome of a cell using the lipid nanoparticles provided herein.

COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTION

Resumen de: WO2025129174A1

Tuberculosis (TB) remains a leading cause of death from infectious disease worldwide, in part due to the limited efficacy of currently available vaccine. Disclosed herein are compositions and methods for providing immunogenic protection against TB.

STABILIZATION OF LIPID NANOPARTICLE FORMULATIONS

Resumen de: WO2025128958A1

Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a citrate drug product matrix, EDTA drug product matrix, methionine drug product matrix, and/or a tryptophan drug product matrix. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.

METHODS OF TREATING A CANCER IN AN INDIVIDUAL

Resumen de: WO2025129108A1

The present application, in certain aspects, pertains to methods of treating a cancer in an individual using a composition comprising nanoparticles comprising an mTOR inhibitor (such as sirolimus) and an albumin. In some aspects, the methods are directed to an individual subjected to two or more prior treatments. In other aspects, the methods are directed to a cancer of the adrenal cortex. In certain aspects, provided are methods of reducing the size of a tumor and/ or reducing a tumor-associated fluid accumulation using a composition comprising nanoparticles comprising an mTOR inhibitor (such as sirolimus) and an albumin.

LIPID COMPOUNDS AND USES THEREOF

Resumen de: WO2025126113A1

Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, G1, L1, L2, R2, R3, a, and b are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

LIPID COMPOUNDS AND USES THEREOF

Resumen de: WO2025126118A1

Compounds are provided having the following structure (I) or a pharmaceutically acceptable salt, N-oxide, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, G1, G2 and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a nucleic acid, compositions comprising the compounds and methods for their use and preparation are also provided.

COMPOSITIONS AND METHODS FOR NON-VIRAL DELIVERY OF THERAPEUTIC COMPOUNDS

Resumen de: WO2025129128A1

The present disclosure provides compositions and methods for non-viral delivery of therapeutics, and methods of preparing said compositions.

HYDROGELS COMPRISING PROTEIN-STABILIZED NANOPARTICLES FOR EXTENDED RELEASE

Resumen de: WO2025128639A1

The present disclosure provides compositions comprising a hydrogel and a protein-stabilized nanoparticle. The hydrogel comprises a crosslinked protein matrix, the protein-stabilized nanoparticle comprises a therapeutic agent or a diagnostic agent, and the protein-stabilized nanoparticle is embedded in the crosslinked protein matrix. The compositions thus provide a means of controlled and prolonged delivery of therapeutic and diagnostic agents. The present disclosure further provides kits comprising the compositions, methods of treating or preventing a disease or disorder, and methods of preparing the compositions.

INHIBITION OF ENDOSOMAL ESCAPE DETECTION TO AMELIORATE THE INFLAMMATORY SIDE-EFFECTS OF LIPID NANOPARTICLES

Resumen de: WO2025128913A1

Composition and methods for preventing or reducing inflammation resulting from nanoparticle administration to a subject are provided. In one embodiment a method of delivering an agent to a target organ of a subject, comprises administering to the subject a galectin inhibitor and a nanoparticle comprising the agent, wherein inflammation resulting from administration of the nanoparticle is reduced or prevented.

CRISPRI TARGETING ALPHA-SYNUCLEIN

Resumen de: WO2025128134A1

A composition and a method of treatment for treatment of diseases related to overexpression of SNCA gene in a subject such as Parkinson's disease comprising one or more clustered regularly interspaced short palindromic repeats associated protein (Cas9) or a variant thereof and one or more guide ribonucleic acids (RNAs). The present invention also provides a nanoparticle encapsulating any embodiment of the composition of the present invention.

NANODISCS COMPRISING FAB FRAGMENTS AND FC FRAGMENTS OF ANTIBODY AND ANTIVIRAL USE THEREOF

Resumen de: WO2025127239A1

The present invention relates to nanodiscs comprising Fab or scFv fragments and Fc fragments of an antibody and a use thereof. The nanodiscs of the present invention comprising Fab or scFv fragments and Fc fragments show higher production yield compared to conventional nanodiscs, exhibit excellent pharmacokinetic properties, and may demonstrate excellent antiviral efficacy. In addition, the nanodiscs of the present invention comprising Fab or scFv fragments and Fc fragments can be used as an antibody-drug conjugate (ADC) platform. In particular, drugs loaded onto the nanodiscs of the present invention comprising Fab or scFv fragments and Fc fragments may exhibit improved pharmacokinetic characteristics such as in vivo half-life, bioavailability, and activity.

LIPID FOR ENHANCING IMMUNOGENICITY OF MRNA/LNP VACCINE

Resumen de: WO2025127402A1

The present invention relates to a lipid for enhancing the immunogenicity of mRNA/LNP vaccines and, more specifically, to a lipid nanoparticle comprising a lipid that includes propionate, butyrate, or both, and a drug delivery carrier utilizing same. The lipid nanoparticle according to the present invention can significantly enhance the immunogenicity of a nucleic acid-based vaccine contained therein.

LIPID NANOPARTICLES COMPRISING CODING RNA MOLECULES FOR USE IN GENE EDITING AND AS VACCINES AND THERAPEUTIC AGENTS

Resumen de: WO2025128871A2

The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and/or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and/or therapeutic agents.

IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES, AND METHODS OF SYNTHESIS AND USE THEREOF

Resumen de: WO2025128902A1

Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (e.g., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.

CATIONIC LIPID COMPOUNDS FOR USE IN LIPID NANOPARTICLES

Resumen de: WO2025128696A1

Compounds are provided having the following Formula (I): or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3a, R3b, R3c, R3d, L1, L2, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

GLYCOLIPID COMPOSITIONS

Resumen de: WO2025125385A1

Provided herein are particles and compositions comprising one or more glycolipids and a nucleic acid, wherein the one or more glycolipids are represented by, for example, formula I or a pharmaceutically acceptable salt thereof.

HYDROGEL COMPOSITIONS

Resumen de: WO2025125384A1

The present invention relates to compositions comprising metal-organic framework (MOF) nanoparticle or nanoparticles, methods of preparing said compositions, methods of treatment using said compositions, and uses of said compositions.

NUCLEIC ACID SEQUENCE(S) AND CONSTRUCT(S) FOR TREATING METHYLMALONIC ACIDEMIA AND METHOD(S) THEREOF

Resumen de: WO2025126242A1

The present disclosure provides a nucleic acid sequence encoding MMUT for the treatment of Methylmalonic acidemia (MMA). Said nucleic acid is codon optimized to improve various parameters and allows high expression in the cells it is expressed in. The present disclosure also provides nucleic acid construct(s) comprising the nucleic acid sequence encoding MMUT along with one or more regulatory elements. Modes of delivery of the said nucleic acid sequence include delivery by way of encapsulation in a lipid nanoparticle when the nucleic acid is an mRNA and by way of a recombinant AAV vector when the nucleic acid is a DNA sequence. The present disclosure also relates to a composition and kit comprising the nucleic acid sequence, constructs or delivery vehicles as well as their applications in treating MMA.

PREPARATION AND USE OF ALBUMIN-PACLITAXEL TWIN DRUG NANOPARTICLE

Resumen de: WO2025124615A2

The present invention belongs to the technical field of pharmaceutical chemistry and biopharmaceuticals. Disclosed in the present invention are the preparation and use of an albumin-paclitaxel twin drug nanoparticle. The preparation particularly relates to mixing albumin with water to prepare an albumin solution; mixing paclitaxel or a paclitaxel twin drug compound with an organic solvent to obtain a drug solution; and mixing the albumin solution with the drug solution, and performing ultrasonic dispersion, and then rotary evaporation and ultrafiltration to prepare an albumin-binding paclitaxel or albumin-paclitaxel twin drug nanoparticle. With regard to the albumin-paclitaxel twin drug prepared in the present invention, drug accumulation in tumors can be increased by means of using the special GP60-caveolin-SPARC transport mechanism of albumin. Both in-vivo and in-vitro experiments prove that the albumin-paclitaxel twin drug nanoparticles of the present invention have a good anti-tumor effect.

COMPOSITION AND COMPOUND FOR DELIVERING THERAPEUTIC AGENT

Resumen de: WO2025124560A1

A lipid nanoparticle composition for delivering a therapeutic agent, comprising a compound of formula I or compounds of formula I and formula II, or a salt thereof.

BREAST-CANCER-TARGETED MILK-DERIVED EXOSOME DRUG DELIVERY SYSTEM, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: WO2025123664A1

Disclosed are a breast-cancer-targeted milk-derived exosome drug delivery system, and a preparation method therefor and the use thereof, which belong to the technical field of pharmaceuticals. The method for preparing the breast-cancer-targeted milk-derived exosome drug delivery system involves: adding sodium citrate to animal milk to remove casein, performing differential centrifugation under a low-temperature condition by using a centrifuge, separating and enriching milk-derived exosomes, performing ultrasonic drug loading on the drug solution and the milk-derived exosome suspension at 37°C, and performing freeze drying to obtain drug-loaded exosomes. In the preparation method, the exosomes are obtained by taking animal milk as a source. The source of animal milk is abundant and the operation of the method is simple, which reduces the production cost. Moreover, natural ligands on the milk-derived exosomes can specifically target and bind to breast-cancer cells, so that uptake by cancer cells is enhanced, the cytotoxicity of the drug to normal cells is reduced, and the effect of specifically treating breast cancer is achieved. The present application is widely used in the field of targeted delivery of drugs for breast cancer treatment.

PROTEIN CARRIER-BASED ACTIVE INGREDIENT TRANSDERMAL DELIVERY SYSTEM, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025123597A1

A protein carrier-based active ingredient transdermal delivery system, which is a small molecule active ingredient-protein-polymer composite structure and comprises a small molecule active ingredient, a protein loaded with the small molecule active ingredient, and a polymer coating a surface of the protein. The protein is modified with a polymerizable double-bond compound. After the loading of the small molecule active ingredient, a polymerization reaction is initiated on the surface of the protein in situ, so that the surface of the protein is coated with a polymer layer. The polymer layer is biologically friendly, and the surface properties of the polymer layer can be regulated and controlled according to the transdermal depth requirement, thereby achieving the targeted transdermal delivery of proteins and active small molecules while breaking through the skin barrier, and significantly overcoming the defect of poor delivery efficiency of previous protein-based delivery systems. The transdermal delivery system has a simple preparation method with a high yield, and thus can be industrially produced on a large scale.

NANOPARTICLE LOADED WITH PHOTOSENSITIZER CE6 AND TARGETING MITOCHONDRIA OF BREAST CANCER CELLS, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Nº publicación: WO2025123478A1 19/06/2025

Solicitante:

QILU UNIV OF TECHNOLOGY SHANDONG ACADEMY OF SCIENCES [CN]
\u9F50\u9C81\u5DE5\u4E1A\u5927\u5B66 \uFF08\u5C71\u4E1C\u7701\u79D1\u5B66\u9662\uFF09

Resumen de: WO2025123478A1

The present invention provides a nanoparticle loaded with a photosensitizer Ce6 and targeting mitochondria of breast cancer cells, and a preparation method therefor and a use thereof. The nanoparticle uses hollow mesoporous silica as a carrier; a photosensitizer Ce6 is loaded at the hollow position of the carrier; a red cell membrane is encapsulated outside the carrier; and one side of the carrier after being encapsulated by the red cell membrane is modified with a Pt nanocluster, and the other side of the carrier is modified with an LXL-1 aptamer and TPP. The present invention also provides a preparation method for the nanoparticle and a use of the nanoparticle in preparation of a drug for treating breast cancer.